| Literature DB >> 34881188 |
Shuai Chang1, Kun Zhou1,2, Yan Wang1, Yutian Lai1,3, Guowei Che1.
Abstract
OBJECTIVES: Cough impairment may lead to excessive accumulation of pulmonary secretions and increase the risk of postoperative pulmonary complications (PPCs). Peak expiratory flow (PEF) is a sensitive indicator of cough ability. We aimed to investigate the correlation between PEF and PPCs for lung cancer patients undergoing lobectomy or segmental resection for improved risk assessment.Entities:
Keywords: lung neoplasms; peak expiratory flow (PEF); postoperative pulmonary complications; pulmonary rehabilitation; pulmonary surgical procedures
Year: 2021 PMID: 34881188 PMCID: PMC8645567 DOI: 10.3389/fonc.2021.782774
Source DB: PubMed Journal: Front Oncol ISSN: 2234-943X Impact factor: 6.244
Baseline and clinical characteristics between the PPCs groups and non-PPCs group.
| Variables | PPCs group ( | non-PPCs group ( |
|
|---|---|---|---|
| Age (years), mean ± SD | 64.6 ± 8.9 | 61.0 ± 8.6 | <0.001 |
| BMI (kg/m2), mean ± SD | 23.3 ± 3.1 | 23.4 ± 2.9 | 0.667 |
| Gender, | 0.063 | ||
| Male | 67 (64.4%) | 248 (54.4%) | |
| Female | 37 (35.6%) | 208 (45.6%) | |
| Pulmonary function, mean ± SD | |||
| PEF (L/min) | 294.2 ± 95.7 | 363.0 ± 105.6 | <0.001 |
| FEV1 (L) | 2.0 ± 0.6 | 2.4 ± 0.7 | <0.001 |
| FEV1% | 86.5 ± 23.6 | 99.0 ± 20.8 | <0.001 |
| Smoking status, | <0.001 | ||
| Current or former smokers | 71 (68.3%) | 210 (46.1%) | |
| Non-smokers | 33 (31.7%) | 246 (53.9%) | |
| Comorbidities, | |||
| Diabetes | 15 (14.4%) | 49 (10.7%) | 0.287 |
| Hypertension | 30 (28.8%) | 120 (26.3%) | 0.599 |
| COPD | 46 (46.9%) | 105 (25.1%) | <0.001 |
| Surgical approach, | <0.001 | ||
| Open | 41 (39.4%) | 94 (20.6%) | |
| VATS | 63 (60.6%) | 362 (79.4%) | |
| Resection type, | 0.002 | ||
| Lobectomy | 78 (75.0%) | 267 (58.6%) | |
| Sublobar resection | 26 (25.0%) | 189 (41.4%) | |
| Operation time (min), mean ± SD | 142.7 ± 49.6 | 112.4 ± 47.2 | <0.001 |
| Pathological type, | 0.123 | ||
| Adenocarcinoma | 56 (53.9%) | 286 (62.7%) | |
| Squamous carcinoma | 33 (31.7%) | 102 (22.4%) | |
| Other NSCLC | 15 (14.4%) | 68 (14.9%) | |
| Pathological stage, | 0.712 | ||
| Stage I | 59 (56.7%) | 276 (60.5%) | |
| Stage II | 26 (25.0%) | 98 (21.5%) | |
| Stage III+IV | 19 (18.3%) | 82 (18.0%) | |
| Postoperative stay, mean ± SD | 9.8 ± 4.1 | 5.6 ± 2.2 | <0.001 |
| Hospitalization expenses ($), mean ± SD | 9,359 ± 2,134 | 7,305 ± 1,884 | <0.001 |
BMI, body mass index; PEF, peak expiratory flow; FEV1, forced expiratory volume in 1 second; COPD, chronic obstructive pulmonary disease; VATS, video-assisted thoracoscopic surgery; NSCLC, non–small cell lung cancer.
Univariate and multivariable analysis for risk factors of PPCs.
| Variables | Category | Univariate analysis | Multivariable analysis | ||||
|---|---|---|---|---|---|---|---|
| OR | 95% CI |
| OR | 95% CI |
| ||
| Age | <70, ≥70 | 2.089 | 1.291-3.380 | 0.003 | 1.746 | 0.951-3.205 | 0.072 |
| Gender | F, M | 1.519 | 0.976-2.362 | 0.064 | 0.469 | 0.162-1.359 | 0.163 |
| PEF | Per unit increase | 0.993 | 0.990-0.995 | <0.001 | 0.991 | 0.987-0.995 | <0.001 |
| PEF(male) | ≥320,<320 | 4.667 | 2.643-8.241 | <0.001 | – | – | – |
| PEF(female) | ≥250,<250 | 4.929 | 2.364-10.276 | <0.001 | – | – | – |
| FEV1 | Per unit increase | 0.438 | 0.306-0.627 | <0.001 | 1.392 | 0.718-2.698 | 0.328 |
| FEV1% | ≥70, <70 | 4.170 | 2.429-7.159 | <0.001 | 2.145 | 0.957-4.809 | 0.064 |
| Lobectomy | Yes | 2.124 | 1.132-3.437 | 0.002 | 1.604 | 0.918-2.803 | 0.097 |
| Smoking status | Yes | 2.510 | 1.597-3.945 | <0.001 | 5.457 | 1.980-15.038 | 0.001 |
| Diabetes | Yes | 1.400 | 0.751-2.608 | 0.289 | – | – | – |
| Hypertension | Yes | 1.135 | 0.708-1.821 | 0.599 | – | – | – |
| COPD | Yes | 2.637 | 1.674-4.153 | <0.001 | 1.198 | 0.642-2.235 | 0.570 |
| VATS procedure | Yes | 0.399 | 0.253-0.628 | <0.001 | 0.542 | 0.316-0.929 | 0.026 |
| Operation time | <3 h, ≥3 h | 2.805 | 1.582-4.974 | <0.001 | 3.529 | 1.840-6.769 | <0.001 |
PEF, peak expiratory flow; FEV1, forced expiratory volume in 1 second; COPD, chronic obstructive pulmonary disease; VATS, video-assisted thoracoscopic surgery.
Figure 1The incidence of PPCs in different ranges of PEF.
Figure 2ROC analysis on discriminative power of PEF for predicting risk of PPCs in (A) female and (B) male groups.
Clinical characteristics and outcomes between female patients divided by cutoff value of PEF.
| Variables | PEF ≤ 250 L/min ( | PEF > 250 L/min ( |
|
|---|---|---|---|
| Age (years), mean ± SD | 65.4 ± 7.8 | 59.3 ± 8.9 | <0.001 |
| BMI (kg/m2), mean ± SD | 23.6 ± 3.5 | 23.1 ± 2.9 | 0.297 |
| Pulmonary function, mean ± SD | |||
| PEF (L/min) | 214.1 ± 37.8 | 337.7 ± 50.8 | <0.001 |
| FEV1 (L) | 1.6 ± 0.4 | 2.1 ± 0.4 | <0.001 |
| FEV1% | 91.6 ± 24.1 | 108.4 ± 18.3 | <0.001 |
| Smoking history, | 6 (8.0%) | 6 (3.5%) | 0.138 |
| Comorbidities, | |||
| Diabetes | 13 (17.3%) | 13 (7.6%) | 0.023 |
| Hypertension | 29 (38.7%) | 39 (22.9%) | 0.011 |
| COPD | 28 (40.6%) | 12 (7.1%) | <0.001 |
| Surgical approach, | 0.164 | ||
| Open | 18 (24.0%) | 28 (16.5%) | |
| VATS | 57 (76.0%) | 142 (83.5%) | |
| Operation time (min), mean ± SD | 123.4 ± 46.8 | 113.3 ± 47.2 | 0.123 |
| Postoperative stay, mean ± SD | 7.0 ± 3.1 | 5.5 ± 2.7 | 0.001 |
| Hospitalization expenses ($), mean ± SD | 7,704 ± 2136 | 7,117 ± 2,075 | 0.045 |
| Drug cost ($), mean ± SD | 1,228 ± 568 | 977 ± 499 | 0.001 |
| PPCs rate, | 23 (30.7%) | 14 (8.2%) | <0.001 |
| Pneumonia | 15 (20.0%) | 9 (5.4%) | <0.001 |
| Atelectasis | 6 (8.0%) | 5 (2.9%) | 0.153 |
| Air leak | 3 (4.0%) | 4 (2.4%) | 0.766 |
| Pneumothorax | 1 (1.3%) | 3 (1.8%) | 0.763 |
| Pleural effusion | 0 (0.0%) | 2 (1.2%) | 1.000 |
| Mechanical ventilation >48 h | 1 (1.3%) | 0 (0.0%) | 1.000 |
| Bronchopleural fistula | 0 (0.0%) | 0 (0.0%) | 1.000 |
| Pulmonary embolism | 0 (0.0%) | 1 (0.6%) | 1.000 |
BMI, body mass index; PEF, peak expiratory flow; FEV1, forced expiratory volume in 1 second; COPD, chronic obstructive pulmonary disease; VATS, video-assisted thoracoscopic surgery.
Clinical characteristics and outcomes between male patients divided by cutoff value of PEF.
| Variables | PEF ≤ 320 L/min ( | PEF > 320 L/min ( |
|
|---|---|---|---|
| Age (years), mean ± SD | 64.7 ± 8.3 | 60.8 ± 8.8 | <0.001 |
| BMI (kg/m2), mean ± SD | 23.1 ± 2.8 | 23.6 ± 2.8 | 0.142 |
| Pulmonary function, mean ± SD | |||
| PEF (L/min) | 261.7 ± 47.9 | 445.3 ± 83.2 | <0.001 |
| FEV1 (L) | 2.0 ± 0.5 | 2.8 ± 0.6 | <0.001 |
| FEV1% | 74.2 ± 18.3 | 99.3 ± 16.8 | <0.001 |
| Smoking history, | 87 (90.6%) | 182 (83.1%) | 0.082 |
| Comorbidities, | |||
| Diabetes | 12 (12.5%) | 26 (11.9%) | 0.875 |
| Hypertension | 24 (25.0%) | 58 (26.5%) | 0.782 |
| COPD | 64 (66.7%) | 47 (21.5%) | <0.001 |
| Surgical approach, | 0.010 | ||
| Open | 25 (26.0%) | 64 (29.2%) | 0.564 |
| VATS | 71 (74.0%) | 155 (71.8%) | |
| Operation time (min), mean ± SD | 124.7 ± 54.8 | 117.2 ± 51.4 | 0.256 |
| Postoperative stay, mean ± SD | 8.8 ± 3.9 | 6.9 ± 3.1 | <0.001 |
| Hospitalization expenses ($), mean ± SD | 8,294 ± 2,174 | 7,804 ± 1,926 | <0.001 |
| Drug cost($) | 1,726 ± 699 | 1,299 ± 582 | <0.001 |
| PPCs rate, | 39 (40.6%) | 28 (12.8%) | <0.001 |
| Pneumonia | 30 (31.3%) | 20 (9.1%) | <0.001 |
| Atelectasis | 8 (8.3%) | 9 (4.1%) | 0.126 |
| Air leak | 12 (12.5%) | 12 (5.5%) | 0.031 |
| Pneumothorax | 4 (4.2%) | 5 (2.3%) | 0.578 |
| Pleural effusion | 4 (4.2%) | 3 (1.4%) | 0.256 |
| Mechanical ventilation >48 h | 1 (1.0%) | 1 (0.5%) | 1.000 |
| Bronchopleural fistula | 0 (0.0%) | 1 (0.5%) | 1.000 |
| Pulmonary embolism | 2 (2.1%) | 0 (0.0%) | 1.000 |
BMI, body mass index; PEF, peak expiratory flow; FEV1, forced expiratory volume in 1 second; COPD, chronic obstructive pulmonary disease; VATS, video-assisted thoracoscopic surgery.